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Symptomatic dengue virus infection ranges in disease severity from an influenza-like illness to life-threatening shock. One
model of the mechanism underlying severe disease proposes that weakly neutralizing, dengue serotype cross-reactive antibodies
induced during a primary infection facilitate virus entry into Fc receptor-bearing cells during a subsequent secondary infection,
increasing viral replication and the release of cytokines and vasoactive mediators, culminating in shock. This process has been
termed antibody-dependent enhancement of infection and has significantly hindered vaccine development. Much of our under-
standing of this process has come from studies using mouse monoclonal antibodies (MAbs); however, antibody responses in
mice typically exhibit less complexity than those in humans. A better understanding of the humoral immune response to natural
dengue virus infection in humans is sorely needed. Using a high-efficiency human hybridoma technology, we isolated 37 hybrid-
omas secreting human MAbs to dengue viruses from 12 subjects years or even decades following primary or secondary infection.
The majority of the human antibodies recovered were broadly cross-reactive, directed against either envelope or premembrane
proteins, and capable of enhancement of infection in vitro; few exhibited serotype-specific binding or potent neutralizing activ-
ity. Memory B cells encoding enhancing antibodies predominated in the circulation, even two or more decades following infec-
tion. Mapping the epitopes and activity of naturally occurring dengue antibodies should prove valuable in determining whether
the enhancing and neutralizing activity of antibodies can be separated. Such principles could be used in the rational design of
vaccines that enhance the induction of neutralizing antibodies, while lowering the risk of dengue shock syndrome.
Dengue viruses (DENV) are expanding globally with an esti-mated 50 to 100 million cases of DENV infection occurring
worldwide annually, and more than 20,000 associated deaths. It is
now estimated that approximately one-fifth of the world popula-
tion is at risk of infection by DENV (9, 12, 13). Dengue is also
threatening the continental United States. More than 25 cases of
locally acquired infection were reported in Key West, Florida, in
2009 and 2010 (1). Symptomatic dengue disease ranges in severity
from an influenza-like illness to life-threatening hemorrhagic fe-
ver or shock. Understanding the pathogenesis of dengue hemor-
rhagic fever/dengue shock syndrome (DHF/DSS) is of central im-
portance in the rational development of antiviral for treatment
and vaccines to prevent dengue disease (11, 49).
The DENV complex consists of four serotypes. Infection with a
single serotype leads to antibody responses that cross-react with
all serotypes (14). Despite the cross-reactivity, individuals only
develop protective immunity against the serotype responsible for
infection (14, 43). Human studies have established clearly that the
risk of progressing to DHF is greater during secondary than dur-
ing primary infection (15). A prevailing theory that explains se-
vere dengue during secondary infection is that preexisting, non-
neutralizing dengue-specific antibodies bind to virions and
enhance entry and replication in Fc-receptor-bearing cells, which
leads to a higher viremia and release of cytokines and vasoactive
mediators that increase vascular permeability (15). The molecular
process of antibody-dependent enhancement (ADE) of infection
has been demonstrated to occur with DENV and antibodies using
cells in culture and animal models (16). A better understanding of
the molecular, genetic, and structural basis for recognition of
DENV by human antibodies is greatly needed and could lead to
the rational design of vaccines that enhance the induction of neu-
tralizing antibodies while lowering the risk of DHF/DSS.
DENV are enveloped viruses of the Flaviviridae family that
display pseudo-icosahedral symmetry, with 180 copies of the en-
velope (E) glycoprotein and 180 copies of the membrane (M)
protein in the lipid bilayer membrane. Previous structural studies
have shown that the dengue virus E protein is arranged into 30
rafts of three parallel dimers in mature virion particles (22). En-
velope glycoproteins form dimers, and crystal structures of the
postfusion or dimeric forms of E protein have been determined
for three DENV serotypes (DENV1, DENV2, and DENV3) (27,
29, 30, 51). The E glycoprotein monomer possesses three principal
domains, designated domain I (DI), DII, and DIII. DIII is likely
the recognition domain for the principal cell receptor (4, 6, 18,
39). DII possesses the fusion loop (28) and an N-linked glycan,
which can contribute to cell binding by interaction with
DC-SIGN, a dendritic cell-specific adhesion receptor that is a
C-type lectin (38). Extensive characterization of neutralizing
epitopes on DENV E protein has occurred over the past 10 years,
using monoclonal antibodies (MAbs) generated in mice inocu-
lated multiple times with DENV (14, 15, 43, 45). Mapping of
epitopes recognized by strongly neutralizing mouse MAbs has
identified several major antigenic sites on the E protein (36). Stud-
Received 16 September 2011 Accepted 7 December 2011
Published ahead of print 14 December 2011
Address correspondence to James E. Crowe, Jr., james.crowe@vanderbilt.edu.
Copyright © 2012, American Society for Microbiology. All Rights Reserved.
doi:10.1128/JVI.06335-11
0022-538X/12/$12.00 Journal of Virology p. 2665–2675 jvi.asm.org 2665
ies have shown that sites in the region of the fusion peptide, lo-
cated at the tip of E protein DII (34, 39) and near the E protein
hinge and linker regions between DI and DII, are recognized by
cross-reactive, moderately neutralizing mouse MAbs. The most
potent neutralizing antibodies are serotype specific, however, and
bind epitopes on the lateral surface of DIII of the E protein (29,
33). Investigators also have uncovered specific mechanisms of an-
tibody neutralization of flaviviruses. Some flavivirus antibodies
that neutralize probably do so by sterically blocking attachment
of the virus to the cell receptor. Other neutralizing antibodies
block a step after cell attachment, and such antibodies possibly
neutralize by preventing protein conformational changes re-
quired for viral fusion in endosomes (19, 32). Some antibodies
(for example, the DENV MAb 1A1D-2) appear to bind to hidden
epitopes that are transiently exposed on the particle and promote
a cascade of E protein rearrangements on the particle (26). These
studies have been instrumental in understanding mechanisms for
flavivirus neutralization; however, since the antibodies were gen-
erated artificially in mice, the ability to translate this information
to humans is limited.
The ability of flavivirus MAbs to enhance DENV infection in
cell culture and animal models has been studied extensively (2, 8,
10, 16). ADE of infection has been shown to occur with antibodies
binding to E or prM proteins (8, 17, 20). This phenomenon results
in as much as a 1,000-fold increase in infectivity and is Fc medi-
ated (2, 25). Recent work by Pierson et al., using mouse MAbs
against WNV, has shed light on the stoichiometry of this process
(35, 37). For each antibody studied, a threshold number of MAbs
docked to the virion dictated whether neutralization or enhance-
ment took place. The type of functional activity was determined
not only by the location of the epitope but also by the antibody
affinity and epitope accessibility. An additional mechanism of
ADE has been demonstrated to occur with anti-prM antibodies.
Using either mouse or human MAbs, investigators have shown
that the presence of anti-prM antibodies causes immature viral
particles that have prM on the surface, which are normally non-
infectious, to acquire the ability to infect cells efficiently through
Fc-mediated pathways (8, 40, 41). The role that ADE plays in the
pathogenesis of DENV infection is of significant interest. Charac-
terization of antibodies obtained from humans following natural
infection could prove to be an important tool for further investi-
gation.
Until very recently, the isolation of naturally occurring human
MAbs has been challenging. Most of our knowledge of the human
antibody response to dengue has come from studies using poly-
clonal sera of naturally infected patients. Using antibody deple-
tion experiments, we have previously demonstrated that E protein
DIII binding antibodies make up a small fraction of the anti-
dengue binding and neutralization activity in immune sera (48).
Crill et al. confirmed that serotype-specific DIII antibodies
formed a very small proportion of the polyclonal response; how-
ever, these investigators showed a significant correlation between
the presence of such antibodies and DENV neutralizing activity
(5). Taken together, these studies suggest that very rare serotype-
specific potent neutralizing antibodies may be the primary deter-
minants of protection against severe disease in humans.
Recently, several groups have generated panels of human
DENV-specific MAbs using B cells from people exposed to natural
DENV infection in order to investigate the humoral response to
dengue infection. Schieffelin et al. generated three E protein-
reactive human MAbs and showed that all three were at least par-
tially cross-reactive and two lacked neutralizing activity (44). A
panel of six human anti-prM MAbs was developed and shown to
be entirely cross-reactive and devoid of significant neutraliza-
tion activity (8). Other investigators have isolated larger panels
of human MAbs to dengue virus (3, 7). These studies indicate
that most antibodies are serotype cross-reactive and weakly to
non-neutralizing. Fewer than 5% of the antibodies displayed
moderate to strong neutralization of one or more serotypes.
In the present study, we use a high-efficiency optimized
method to generate human hybridomas to make a large panel of
MAbs to DENV derived from peripheral blood cells of travelers
following natural primary or secondary infections.
MATERIALS AND METHODS
Viruses and recombinant proteins. DENV1 WestPac-74, DENV2
S-16803, DENV3 CH-53489, and DENV4 TVP-360, provided by Robert
Putnak (Walter Reed Army Institute of Research, Silver Spring, MD),
were used in the present study. These viruses were used to prepare infec-
tious stocks and purified DENV antigens as previously described (48). A
pure virus antigen mixture containing equal quantities of each of the four
serotypes were used to screen and characterize human hybridomas. Re-
combinant proteins containing fragments of E or prM were used to de-
termine antigens and domains recognized by human antibodies. Recom-
binant envelope (rE) proteins (80% of E protein) from the four DENV
serotypes were purchased from Hawaii Biotech, Inc. (27). This antigen
binds to conformational MAbs, and X-ray crystallography studies have
demonstrated that these proteins retained a native-like structure (27, 29).
DIII of E protein from each of the four serotypes was expressed as fusion
protein with maltose-binding protein (MBP) in E. coli and purified as
previously described (27). These proteins also bind to conformational
MAbs and retain native-like structure (27). Purified DENV2 proteins
containing DI and II of envelope and pr peptide of prM were kindly
provided by M. Kielian and A. Zheng from Albert Einstein College of
Medicine, New York, NY (24, 52).
Human subjects and peripheral blood cell isolation. We identified a
panel of 12 dengue-immune subjects in North Carolina by screening vol-
unteers who suspected exposure during past travel to regions where den-
gue is endemic. We confirmed DENV infection by testing patient sera for
the presence of antibodies that neutralized one or more DENV serotypes.
In most laboratory-confirmed cases we were able to pinpoint the year and
country of infection by taking a detailed travel and clinical history. From
dengue-immune subjects 100 ml of blood was collected by venipunc-
ture and immediately processed to isolate peripheral blood mononuclear
cells (PBMCs) by density gradient separation on Ficoll. The cells were
immediately cryopreserved and stored in liquid nitrogen. The protocol
for recruiting and collecting blood samples from people was approved by
the Institutional Review Board of the University of North Carolina at
Chapel Hill.
Generation of human hybridomas. Previously cryopreserved sam-
ples were thawed rapidly in a 37°C water bath and washed once in 10 ml of
prefusion medium (ClonaCell-HY 03801; Stemcell Technologies). The
cells were counted, and viability was assessed with trypan blue staining
(Gibco 15250-061). For every 4 million viable cells, the following was then
added: 13 ml of warmed prefusion medium, 20 l of CpG stock (2.5
mg/ml; ODN 2006; Invivogen tlrl-hodnb-5), 20 l of cyclosporine stock
(1 mg/ml in ethanol; Sigma catalog no. C1832), 20 l of Chk2i stock (10
mM; Sigma catalog no. C3742), and 4.5 ml of clarified supernatant from
cultures of B95.8 cells (ATCC VR-1492) containing Epstein-Barr virus
(EBV). The mixture then was plated into 384-well plates (Nunc catalog
no. 164688) at 50 l/well, and plates were incubated at 37°C with 5% CO2
for 10 days, prior to screening for antigen-specific cell lines using an
enzyme-linked immunosorbent assay (ELISA). Cells from wells with su-
pernatants reacting in a DENV-specific ELISA were then expanded by
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collecting all cells in the well and transferring them to a 96-well flat bottom
plate (Falcon catalog no. 353072) in 200 l of prefusion medium contain-
ing irradiated human PBMCs, as follows. We used 20 ml of prefusion
medium, 20 l of CpG stock, 20 l of Chk2i stock, and 8 million heterol-
ogous healthy donor PBMCs that had been gamma-irradiated with 3,000
rads. Plates were incubated at 37°C for 4 days before exchanging 100 l of
medium with fresh prefusion medium. The plates then were incubated for
an additional 3 to 4 days prior to fusion with HMMA2.5 nonsecreting
myeloma cells (kindly provided by Marshall Posner).
Screening ELISA. Gradient-purified DENV prepared in carbonate
binding buffer was used to coat ELISA plates (Nunc catalog no. 242757)
and then UV inactivated using a calibrated UV light source (Stratalinker;
Stratagene) for 10 min prior to incubation at 4°C overnight. The plates
then were blocked with 50 l of blocking solution/well by incubation at
room temperature for 1 h. Blocking solution consisted of 10 g of pow-
dered milk, 20 ml of goat serum, 100 ml of 10 phosphate-buffered saline
(PBS), and 0.5 ml of Tween (Sigma 7949) mixed to a 1-liter final volume
with distilled H2O. Plates were washed four times with PBS, and 5 l of
supernatant was transferred from one well of a 384-well plate containing
EBV-transformed B cell lines, using a pin-tool device (V&P Scientific)
into 25 l of blocking solution/well. The plates were incubated at room
temperature for 1 h prior to four additional washes with PBS. Secondary
antibody (goat anti-human Fc; Meridian Life Science, catalog no.
W99008A) was applied at a 1:5,000 dilution in blocking solution using 25
l/well, and the plates were again incubated at room temperature for 1 h.
After four washes with PBS, phosphatase substrate solution (1 mg of phos-
phatase substrate/ml in 1 M Tris aminomethane) (Sigma, catalog no.
S0942) was added at 25 l/well, and the plates were incubated at room
temperature for 3 h before determination of the optical density at 405 nm
on a Molecular Devices plate reader.
Electrofusion of EBV-transformed B cells with myeloma fusion
partner. HMMA2.5 cells were counted and suspended as 10 million
cells/ml in a microcentrifuge tube in 1 ml of warmed cytofusion medium
composed of 300 mM sorbitol (Fisher, catalog no. BP439-500), 0.1 mM
calcium acetate (Fisher, catalog no. AC21105-2500), 0.5 mM magnesium
acetate (Fisher, catalog no. AC42387-0050), and 1.0 mg/ml of bovine
serum albumin (Sigma, catalog no. A2153). After 7 days of expansion in
96-well plates, cells from EBV-transformed B cell wells were pipetted gen-
tly into microcentrifuge tubes containing 1 ml of warmed cytofusion me-
dium. Transformed B cells and HMMA2.5 cells were centrifuged at 900 
g for 4 min, the supernatants were decanted, and the pellets were resus-
pended in 1 ml of cytofusion medium. This process was repeated three
times to ensure equilibration to the cytofusion medium. The cytofusion
medium then was decanted gently from each sample tube such that 100
l remained, and the pellet was retained. HMMA2.5 cells were then re-
suspended in cytofusion medium to achieve a concentration of 10 million
cells/ml. Then, 100 l of HMMA2.5 cell suspension was mixed with each
sample tube, and the mixture of HMMA2.5 and EBV-transformed B cells
was pipetted into cytofusion cuvettes (BTX, catalog no. 450125). The
cuvette then was placed in a modified cytofusion device, using a BTX
cuvette holder (BTX Safety stand, model 630B) and a Cyto-Pulse Sciences
generator (Cyto-Pulse Sciences, catalog no. PA-4000/PA-101), and the
electrical discharge program was run with following settings: a prefusion
AC current of 70 V for 40 s, followed by a DC current pulse of 300 V for
0.04 ms and then a postfusion AC current of 20 V for 30 s. After fusion, the
cuvettes were incubated at 37°C for 30 min. The content of each cuvette
was then added to 20 ml of hypoxanthine-aminopterin-thymidine (HAT)
medium containing ouabain, composed of the following: 500 ml of post-
fusion medium (Stemcell Technologies, catalog no. 03805), one vial 50
HAT (Sigma, catalog no. H0262), and 150 l of a 1-mg/ml stock of
ouabain (Sigma, catalog no. 013K0750). Fusion products then were plated
at 50 l/well into 384-well plates, followed by incubation at 37°C for 21
days before screening hybridomas for antibody production by ELISA.
MAb production and purification. Wells containing hybridomas
producing DENV-specific antibodies were cloned biologically by two
rounds of limiting dilution plating. Once clonality was achieved, each
hybridoma was expanded in postfusion medium (Stemcell Technologies,
catalog no. 03805) until 50% confluent in 75-cm2 flasks (Corning, catalog
no. 430641). For antibody expression, the cells in 75-cm2 flasks were col-
lected with a cell scraper; the hybridomas were washed in serum-free
medium (Gibco Hybridoma-SFM; Invitrogen, catalog no. 12045084) and
split equally among four 225-cm2 flasks (Corning, catalog no. 431082)
containing 250 ml of serum-free medium. The flasks were incubated for
21 days before the medium was clarified by centrifugation and sterile
filtered (0.2-m pore size). The antibodies were purified from clarified
medium by protein G chromatography (GE Life Sciences, protein G HP
columns, catalog no. 17-0404-03).
Neutralization assay. The neutralizing potency of antibodies was
measured using a flow cytometry-based neutralization assay with the
U937 human monocytic cell line stably transfected with DC-SIGN, as
previously described (21).
ADE assays. The ability of antibodies to enhance DENV was measured
by using U937 cells that had not been engineered to express DC-SIGN. In
the absence of the virus attachment factor, these Fc receptor-bearing cells
are only susceptible to infection in the presence of DENV-specific anti-
bodies. Test antibodies were diluted to different concentrations and
mixed with viruses containing 104 FFU in 96-well round-bottom plates
and incubated at 37°C for 45 min. Then, 2  104 U937 cells were added to
the mixture and incubated for 2 h at 37°C. The cells were washed to
remove unbound virus-antibody mixtures and incubated with fresh me-
dium at 37°C. The cells were harvested 24 h later, fixed, and processed for
flow cytometric analysis to determine the percentages of infected cells.
The fold enhancement of ADE activity was expressed as the relative per-
cent increase of infected cells in the DENV-specific antibody-treated sam-
ple compared to the sample treated with a control antibody.
RESULTS
Electrofusion technique for generation of human hybridomas.
For generation of human hybridomas using PBMCs from individ-
uals who had recovered from natural infection, we used an estab-
lished electrofusion method but made several alterations to the
previously published protocol (50). First, we found that the kinet-
ics and efficiency of transformation of human B cells using EBV
with CpG stimulation was improved inhibiting EBV-associated
apoptosis with the addition of a pharmacologic inhibitor of
CHK2, a protein kinase that is activated in response to DNA dam-
age and is involved in cell cycle arrest (31). Also, after EBV trans-
formation of PBMCs and identification of a well producing a
DENV antibody of interest, expansion of EBV-transformed B cells
in the presence of irradiated PBMCs, CpG, and CHK2 inhibitor
greatly increased transformed B cell numbers, resulting in the
greater likelihood of generating the hybridoma of interest by elec-
trofusion. This added step improved the overall efficiency of iso-
lation of hybridomas by at least 2-fold (data not shown). Addi-
tional improvements in throughput and efficiency were achieved
by adapting a different electroporation cuvette system (BTX cat-
alog no. 45-0207, model 630B) from that previously described for
use with a PA-4000/PA-101 electrofusion device (Cyto-Pulse Sci-
ences). This cuvette system allows for the use of standard dispos-
able electroporation cuvettes, permitting cytofusion of two sam-
ples at one time. In addition to the convenience of the disposable
cuvette, a moderate improvement in the efficiency of hybridoma
generation was observed compared to the Cyto-Pulse cuvette sys-
tem (data not shown). Finally, improvement in consistency was
seen with the use of a commercial hybridoma cell culture medium,
typically used for generation and growth of mouse hybridomas
(ClonaCell-HY Medium, Stemcell Technologies). Together, these
modifications resulted overall in a 10-fold increase in the num-
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ber of human hybridomas that could be generated using PBMCs
from immune individuals compared to historical data in our lab-
oratory.
Demographics and screening of traveler subjects. To better
our understanding of the human antibody response to DENV
following infection, we initiated a study to identify and obtain
blood from people living in North Carolina who had been exposed
to DENV during travel or previous residence in regions where this
disease is endemic. Subjects with a past clinical history compatible
with DENV infection were invited to volunteer. We confirmed a
past DENV infection by identifying the presence of DENV neu-
tralizing antibodies in donor serum, testing against each of the
four DENV serotypes (Table 1). An individual whose serum
mainly neutralized a single serotype was classified as having a his-
tory of infection with a single serotype (“primary”) (Table 1).
Individuals whose serum contained antibodies that broadly neu-
tralized two or more serotypes were considered to have had two or
more previous infections (“secondary”) (Table 1). For secondary
cases, it was not possible to use the neutralization titers to identify
the specific serotypes causing infection or the sequences of the
infecting viruses, since these sera typically recognized all four se-
rotypes. All DENV-immune subjects filled out a detailed ques-
tionnaire about previous travel and clinical history, and this infor-
mation was used to determine the year and location of likely
infection, as well as the interval between infection and sample
collection for the current study (Table 1).
To produce DENV-specific human hybridomas, cryopre-
served PBMC samples from each subject were thawed and inocu-
lated with EBV in the presence of CpG, CHK2 inhibitor, and cy-
closporine, as described in Materials and Methods. As shown in
Table 1, between 744 and 2,976 EBV transformed B cell cultures
were generated from samples from each of the 12 subjects, who
had primary DENV2 (2 subjects) or DENV3 (4 subjects) infection
or a secondary infection (6 subjects). Screening for the presence of
antibodies to dengue virus in the supernatant of transformed B
cell cultures showed that between 0.4 and 5% of wells in the 384-
well transformations were positive. Based on the number of pos-
itive wells and the number of lymphocytes tested, the frequency of
DENV-specific B cells in circulation was estimated for each sub-
ject (Table 1). The frequency was based on the total number of B
cells plated (estimated as 5% of the total PBMCs), with an esti-
mated 10% EBV transformation efficiency (based on average col-
ony counts in transformed wells). A total of 37 human anti-DENV
hybridomas were generated from 12 different subjects, with a
yield ranging from 1 to 10 hybridomas per subject. Twenty-
eight hybridomas were derived from individuals who had pri-
mary infection, and nine were derived from individuals who
had suffered from secondary infection. Remarkably, five hy-
bridomas were derived from the cells of subjects who had been
infected with DENV 20 years or more prior to PBMC collec-
tion. Antibodies secreted by each of the 37 human hybridoma
cell clones were purified and characterized to determine their
DENV protein specificity. Twenty-nine MAbs bound the E
protein, while eight bound the prM protein.
Characteristics of E protein binding human MAbs. Results of
the characterization of 29 purified human anti-E MAbs from anti-
dengue hybridomas are shown in Table 2. Hybridomas derived
from subjects 3, 19, 103, and 105 comprise the majority (23 of the
29 anti-E MAbs generated). Cells were obtained from these sub-
jects following a primary infection. The remaining six anti-E an-
tibodies were derived from six individuals following either pri-
mary or secondary infection. Three anti-E MAbs (designated 4G9,
2C2, and 3H4) were IgG2 molecules, while the rest were of the
IgG1 isotype. Of the anti-E MAbs generated, 12 used kappa light
chains and 17 used lambda light chains.
As seen in Table 2, 29 of the 37 human anti-dengue MAbs
bound to E protein in either ELISA or Western blot assay. Of the
29 anti-E antibodies characterized, all but 3 were fully cross-
reactive, binding all four dengue serotypes in ELISA at the lowest
concentration tested (1 ng/l). Two antibodies, MAbs 5J20 and
2D7, were considered partially cross-reactive, since they bound to
more than one but less than four serotypes. The DENV2 serotype-
specific MAb 2D22 bound only to purified DENV2 virus in ELISA.
Next, we determined the binding of these MAbs to recombinant E























obtainedD1 D2 D3 D4
Primary 2 19 Thailand 1997 8 95  20 105 79/1,860 9.3 10
31 South Pacific 1997 8 20 320 40 20 9/2,232 1.8 1
3 3 Thailand 2001 4 30 87 338  37/744 9.2 7
5 Puerto Rico 2001 4     21/1,860 5.2 1
103 Nicaragua 1995 14   278  12/1,860 2.5 3
105 Thailand 2002 7   210  25/2,232 4.5 6
Secondary Multiple 8 Haiti 1982–1984 21 640 611 213 319 7/744 2.0 1
9 India/Sri Lanka 2000 5   290 393 23/2,976 4.2 1
15 West Indies 1972–1982 23 371 320 288  12/2,232 1.6 1
27 Thailand/Cambodia 1981 24    285 33/1,488 6.3 3
110 Kuala Lumpur 1998–1999 10 205  153 96 49/2,232 9.5 2
115 Sri Lanka 1974–1997 12 90 134 330 165 6/1,488 1.7 1
a , Titer  1:1,280; , titer  1:20. D1, D2, D3, and D4, DENV1, DENV2, DENV3, and DENV4.
b Frequency was estimated based on the total number of B cells plated (an average of 5 % of total PBMCs) with an estimated 10% EBV transformation efficiency, based on colony
counts in the transformation plates.
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protein in ELISA. All but five MAbs bound recombinant E protein
in ELISA. E protein-specific MAbs that did not bind recombinant
E protein were shown to bind E protein using Western blotting,
with the exception of 2D22. DENV2 serotype-specific antibody
2D22 did not bind to structural proteins in Western blot or to
recombinant E protein constructs in ELISA in our studies; how-
ever, it appears to be E protein specific based on preliminary es-
cape mutant studies (R. de Alwis, unpublished data). Finally, we
evaluated the ability of the 29 anti-E MAbs to bind domains I and
II (DI/II) or domain III (DIII) fragments of the E protein. Five
antibodies bound the DIII portion of the E protein: 1C17, 1M23,
2J20, 1B23, and 1M19. Antibodies that did not bind recombinant
domain III of the E protein were tested in ELISA for binding to
DI/II of the E protein. All of the anti-E protein antibodies that did
not bind DIII (except for 2D22; i.e., 23 of 29 anti-E protein anti-
bodies) bound DI/II.
The ability of these 29 human anti-E protein MAbs to neutral-
ize representative viruses of the four dengue serotypes is shown in
Table 2. Interestingly, six antibodies exhibited little or no neutral-
izing activity (50% virus neutralization concentration [Neut50] 
10 g/ml) against any of the four dengue serotypes. Most of the
MAbs, 13 of 29, were found to neutralize viruses weakly for three
or four serotypes, with equivalent potency against those viruses.
Seven antibodies were found to neutralize only one or two sero-
types weakly. Of the 29 antibodies determined to bind E protein,
only three—2D22, 5J7, and 2J20 —were determined to have mod-
erate to strong (Neut50  1 g/ml) neutralizing activity against at
least one serotype.
In Fig. 1, the concentration-dependent neutralization activity
of two strongly neutralizing human anti-E protein MAbs is pre-
sented. The percent neutralizations for the four dengue serotypes
are shown in panel A for MAb 5J7. This MAb, which was isolated
from an individual who recovered from a primary DENV 3 infec-
tion, cross-reacted with all four serotypes and bound to an epitope
on DI/II of E protein (Table 1). Despite the serotype cross-
reactivity in binding assays, MAb 5J7 neutralized only serotype
DENV3 virus. In panel C, the concentration-dependent neutral-
ization activity of MAb 5J7 is shown in greater detail, using a
broader range of halving dilutions. MAb 5J7 neutralized 50% of
serotype DENV3 at a concentration of 0.1 g/ml. The percent
neutralization for MAb 2D22 against viruses from the four DENV
serotypes is shown in Fig. 1B and D. This antibody, which was
isolated from a subject exposed to a primary DENV2 infection,
bound to DENV2 virions but not to rE protein (Table 1). In panel
B, MAb 2D22 is shown to have neutralizing activity only to the
DENV2 serotype. MAb 2D22 exhibited 50% neutralization of
DENV2 at a concentration of 0.08 g/ml (Fig. 1D). Interestingly,
as can be seen in Fig. 1, the maximum percentages of virus neu-
TABLE 2 Characteristics of envelope (E) protein binding human MAbsa
Type of
































D1 D2 D3 D4 D1 D2 D3 D4 D1 D2 D3 D4
Primary 2 19 1C16 1       ND –  10 9 9 – 9 18 53 11
5M22 1       ND –  7 9 5 – 11 11 42 11
1M19 1       ND  ND – – 10 – 6 8 37 15
4C23 1       ND –  – 7 6 7 15 20 28 11
2A10 1       ND –  7 7 5 8 11 8 52 18
4G9 2       ND –  9 10 7 – 9 5 18 6
5J22 1      –  –  – 10 10 – 6 6 22 6
3F13 1      – – –  – – – – – – 37 –
2D22 1  –  – – – – – – – 0.08 – – – – – –
1B23 1       ND  ND 4 5 2 9 21 11 67 7
31 4N23 1      –  –  – – – – – – 19 5
3 3 2A15 1       ND –  7 7 5 10 10 6 16 5
1A15 1       ND –  – – – – – – 7 –
1C17 1       ND  ND – – 7 – 27 26 43 15
1I17 1       ND –  10 8 8 – 7 12 27 7
1M23 1       ND  ND – – 7 – 9 13 51 7
1L5 1       ND –  10 10 2 10 18 24 34 23
103 2D7 1     –  ND –  3 – 3 – – 25 12 –
2C2 2       ND –  10 1 – 1 6 5 6 –
2D17 1        –  – – – – 13 5 27 –
105 5J20 1  – –    ND –  – – 8 – – – 122 15
3I6 1       ND –  – – 7 – 10 – 15 13
5J7 1       ND –  – – 0.1 – – – 23 –
6K5 1       ND –  7 5 10 – 40 5 29 13
Secondary Multiple 8 2J20 1       ND  ND 6 – 0.5 – 7 28 22 9
9 2C7 1       ND –  4 1 4 6 22 5 5 24
27 3H9 1       ND –  – – – – – – 5 –
110 6B22 1      – – –  – – – – 12 20 36 10
115 3H4 2       ND –  10 10 2 10 – – – –
a If the antibody did not bind to recombinant E (rE) protein, Western blotting was performed to determine E protein binding as an alternate method. Binding to recombinant DIII
or recombinant DI or DII is also indicated. The concentration at which 50% of the virus was neutralized (Neut50) is shown for each DENV serotype: a dash (–) indicates a Neut50
value of 10 g/ml, Neut50 values between 1.0 and 10.0 g/ml are given, and Neut50 values of 1.0 g/ml are indicated in boldface. ADE assays were performed for each human
antibody (at a concentration of 1 g/ml) against each DENV serotype and are shown as the fold enhancement: a dash indicates a 5-fold enhancement, 5- to 25-fold enhancement
values are given, and 25-fold enhancement values are indicated in boldface. In the absence of antibody, the percentages of U937 cells infected in the ADE assay with DENV1 (D1),
DENV2 (D2), DENV3 (D3), and DENV4 (D4) were 0.06, 0.17, 0.31, and 1.31%, respectively. ND, not determined.
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tralization for MAbs 5J7 and 2D22 were very different. The
maximum percentage of neutralization for MAb 5J7 was nearly
100%, whereas MAb 2D22 could neutralize only about 60% of
virus in the assay at the highest concentration of antibody
tested.
The abilities of the 29 human anti-E MAbs to enhance infec-
tion in vitro are presented in Table 2. ADE assays were performed
at a concentration of 1 g/ml against a virus from each DENV
serotype. Four antibodies did not exhibit enhancing activity (i.e.,
caused 5-fold enhancement) to three or even four dengue sero-
types. Most MAbs, 15 of 29, were found to enhance infection
moderately (5- to 25-fold) for viruses from two to four DENV
serotypes. Of the 29 antibodies tested, 17 had strong (25-fold)
enhancing activity against virus from at least one serotype. Inter-
estingly, MAb 2J20 strongly neutralized DENV3 but strongly en-
hanced DENV2 infection.
In Fig. 2, neutralization or enhancement activity against a het-
erologous DENV4 strain is shown for several representative hu-
man anti-E protein MAbs. Flow cytometric neutralization assays
were performed using U937-DC-SIGN cells, and enhancement
assays were performed with U937 cells lacking DC-SIGN, as de-
scribed in Materials and Methods. In Fig. 2A, data for fully cross-
reactive, weakly neutralizing, and moderately enhancing MAbs
2A15, 1L5, and 2A10 are shown. All three MAbs neutralized 50%
of DENV4 at a concentration of 10 g/ml. These antibodies
enhanced DENV infection moderately, resulting in a 5- to 25-fold
peak increase in the titer of DENV4. In Fig. 2B, the results for fully
cross-reactive, non-neutralizing and nonenhancing MAbs 3F13,
1A15, and 3H9 are shown. All three antibodies bound DENV4,
but they did not neutralize or enhance virus infection effec-
tively. Together, these two principal categories of anti-E pro-
tein antibodies represented the majority of the human MAbs
we isolated from donors with history of previous primary or
secondary DENV infection.
Characteristics of premembrane (prM) protein binding hu-
man MAbs. A significant number of the MAbs that we isolated
were specific for prM protein. The results of the characterization
of purified prM protein-specific human MAbs from anti-dengue
hybridomas are shown in Table 3. Hybridomas derived from sub-
jects 27 and 105 comprise four of the eight anti-M MAbs gener-
ated. The remaining four antibodies were derived from cells from
subjects 3, 5, 15, and 110. In contrast to the findings with anti-E
protein MAbs, an equal number of anti-prM protein MAbs was
generated from subjects following primary or secondary infection.
All of the anti-prM protein MAbs were of the 1 isotype. Of the
anti-prM protein MAbs generated, four had kappa light chains
and four had lambda light chains.
As can be seen in Table 3, 8 of the 37 human anti-DENV MAbs
did not bind E protein in initial analysis, but instead bound to prM
protein in Western blotting analyses. Of the eight anti-prM pro-
tein antibodies characterized, all were fully cross-reactive, binding
all four dengue serotypes in ELISA at the lowest concentration
tested, 1 ng/l. To further characterize these human anti-prM
protein antibodies, we tested their ability to bind the recombinant
“pr” portion of the premembrane protein of DENV2 in ELISA. All
eight MAbs bound recombinant “pr” in ELISA (Table 3). We
FIG 1 Serotype-specific strongly neutralizing E protein binding human MAbs. (A) The ability of purified human MAb 5J7 to neutralize the four serotypes of
DENV is shown over a concentration range. (B) The ability of purified human MAb 2D22 to neutralize the four serotypes of dengue virus is shown over a
concentration range. (C) Purified human MAb 5J7 neutralization of serotype 3 virus over a detailed, broader range of halving dilutions. (D) Purified human MAb
2D22 neutralization of serotype 2 virus over a detailed range of halving dilutions. Flow cytometric neutralization assays were performed using U937-DC-SIGN
cells.
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tested these eight human anti-prM protein MAbs for their ability
to neutralize viruses from each of the four dengue serotypes (Table
3). Interestingly, each exhibited some weak neutralizing activity
against virus from at least one of the four dengue serotypes. Sur-
prisingly, MAbs 2M2 and 2H12 showed moderate to strong neu-
tralization activity against virus of a single serotype.
The ability of the eight human anti-prM protein MAbs to en-
hance infection in vitro is shown in Table 3. ADE assays were
performed at a concentration of 1 g/ml against representative
viruses from each dengue serotype. All but one of the eight MAbs
had strong (25-fold) enhancing activity for virus from at least
one serotype. Interestingly, anti-prM protein MAb 5L20 was
nearly devoid of enhancing activity for viruses of any of the dengue
serotypes in this assay.
Concentration-dependent neutralization and ADE assays were
performed for each of the human anti-prM protein MAbs against
viruses from each of the four dengue serotypes. The results for
several representative MAbs are shown in Fig. 3. The ability of
each anti-prM protein antibody to neutralize and/or enhance in-
fection with DENV1 (Fig. 3A), DENV2 (Fig. 3B), DENV3 (Fig.
3C), or DENV4 (Fig. 3D) is presented. MAbs 4F8, 1G6, and 4E9,
each exhibited similar concentration-dependent neutralization
curves, with Neut50 concentrations of 10 g/ml against viruses
from each dengue serotype. The concentration-dependent neu-
tralization of MAb 5L20, however, differed, exhibiting almost no
neutralizing activity. ADE occurred with MAbs 4F8, 1G6, and 4E9
(as well as 5E6, 2M2, 2H12, and 5G22 [data not shown]). Overall,
all but one anti-prM protein MAb exhibited enhancing activity.
The degree of enhancement varied between 2- and 126-fold, de-
pending on the MAb and the serotype of the virus tested. Interest-
ingly, anti-prM protein MAb 5L20 did not enhance infection in
this assay at any concentration tested.
DISCUSSION
These studies reveal that the human B cell response to DENV
infection is dominated by cross-reactive antibodies with low or no
neutralizing potency and significant potential to enhance infectiv-
ity by Fc-mediated mechanisms. Antibodies with enhancing ac-
tivity were isolated that were directed to both E and prM proteins,
thus conferring the ability to enhance infectivity not only with
mature infectious particles but also with partially or fully imma-
ture particles displaying prM protein that otherwise would be
FIG 2 Cross-reactive poorly neutralizing E protein binding human MAbs. (A)
The ability of purified human MAb 2A15, 2A10, or 1L5 to neutralize or en-
hance DENV 4 is shown over a concentration range. These MAbs represent a
class of fully cross-reactive, weakly neutralizing, and moderately enhancing
antibodies. (B) The ability of purified human MAb 3F13, 1A15, or 3H9 to
neutralize or enhance DENV 4 is shown over a concentration range. These
MAbs represent a class of fully cross-reactive, non-neutralizing, and nonen-
hancing antibodies. Flow cytometric neutralization assays were performed us-
ing U937-DC-SIGN cells. ADE assays were performed using U937 Fc receptor
expressing cells. In the absence of antibody, the percentage of U937 cells in-
fected in the ADE assay with DENV 4 was 2.09%.
TABLE 3 Characteristics of premembrane (prM) protein binding human MAbsa
Type of






















of infection for four
DENV serotypes at 1
g/ml
D1 D2 D3 D4 D1 D2 D3 D4 D1 D2 D3 D4
Primary 3 3 2H12 1       ND – – 0.1 10 14 7 35 9
5 5L20 1        – – – – – – 5 –
105 4E9 1        – – 1 – 7 – 30 21
5G22 1        – – 6 – 40 12 94 46
Secondary Multiple 15 4F8 1        – – 2 5 13 15 57 24
27 2M2 1        1 0.5 2 1 17 8 8 48
1G5 1        – – 5 – 19 20 70 38
110 5E6 1        – – 6 – 23 15 36 13
a The pattern of virus binding to purified virus in ELISA at the lowest concentration tested (1 ng/l) is shown for each serotype. Binding of each antibody to recombinant “pr” fragment of
the membrane protein in ELISA, along with binding prM protein by Western blotting, is indicated. Neutralization assays performed for each antibody are shown against each DENV
serotype: a dash (–) indicates a Neut50 value of 10 g/ml, Neut50 values between 1.0 and 10.0 g/ml are given, and Neut50 values of 1.0 g/ml are indicated in boldface. ADE assays were
performed for each human antibody (at a concentration of 1 g/ml) against each DENV serotype and shown as the fold enhancement: a dash indicates  5-fold enhancement, 5- to 25-fold
enhancement values are given, and 25-fold enhancement values are indicated in boldface. In the absence of antibody, the percentages of U937 cells infected in the ADE assay with DENV1
(D1), DENV2 (D2), DENV3 (D3), and DENV4 (D4) were 0.06, 0.17, 0.31, and 1.31%, respectively. ND, not determined.
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poorly infectious or noninfectious. Remarkably, B cells encoding
these types of antibodies persisted in the circulation for decades
after infection.
Interestingly, however, a few rare, potently neutralizing anti-
bodies that are nearly devoid of enhancing activity were produced
naturally by humans in response to infection. Mapping of the
epitopes recognized by naturally occurring human DENV-specific
antibodies is essential in determining whether these enhancing
and neutralizing activities can be separated. Understanding the
epitopes and activity of these neutralizing antibodies will be crit-
ical for vaccine development, as vaccines that induce high potency
neutralizing antibodies that lack enhancing activity are desirable.
Ideally, the reactivity of epitopes bound by enhancing antibodies
should be reduced or eliminated in candidate antigens during the
rational development of a dengue vaccine, so as to discourage such
dominant recognition of these antigenic features by the humoral
immune response. The goal is that such molecular information
could be used in the rational design of dengue vaccines that en-
hance the induction of protective neutralizing antibodies and re-
duce the risk of development of severe disease.
DENV E protein was the most common protein target of cir-
culating human memory B cells in the present study. Over three-
quarters (29 of 37) of the human anti-dengue antibodies identi-
fied here bound to E protein. We screened for virus-specific
antibodies using purified whole virus preparations that contained
both immature and mature virus particles and all of the virus
structural proteins. Therefore, these results confirm that the bulk
of the human B cell response to exposed structural antigens is
directed toward the E protein. The majority of the anti-E protein
antibodies, 23 of 29, were obtained from subjects following pri-
mary infection. The E protein has been thought to be the domi-
nant antigen following primary and secondary DENV infection,
when evaluated by Western blotting studies using soluble anti-
bodies in polyclonal sera from immune subjects (23). Our studies
show that the pattern of specificity of circulating B cells also re-
flects this predominance. Characterization of the E protein-
specific antibodies showed that most were of the IgG isotype. This
distribution is typical of the profile of most virus-specific re-
sponses in humans and also reflects the predominance of the IgG1
isotype in the circulating human memory B cell population. Light
chain usage was split almost evenly at 12 kappa light chains and 17
lambda light chains. Both isotype and light chain usage suggest
that isolation of clones using the hybridoma method is unbiased,
as expected. Thus, the panel of human antibodies presented here
likely reflects the frequency and specificity of the anti-dengue B
memory cell pool present in circulation following recovery from
primary or secondary infection.
The most striking feature of the anti-E protein antibodies was
the predominance of cross-reactivity. Of the 29 anti-E protein
antibodies characterized, all but 3 were fully cross-reactive, bind-
ing all four dengue serotypes. Considerable attention has been
paid to the DIII portion of the E protein for DENV and other
flaviviruses (7, 27, 33, 46). The importance of the human antibody
response to DIII has been studied extensively, originally using
polyclonal sera and more recently using human MAbs (3, 48).
However, it is clear that epitopes across other regions of the E
protein contribute significantly to human protection (34, 48). The
data here provide additional information, specifically a better un-
derstanding of the frequency of these antibodies in circulation.
Only 5 of the 29 E protein reactive antibodies bound the DIII
FIG 3 Cross-reactive poorly neutralizing prM protein binding human MAbs. The ability of purified human MAb 1G6, 4E9, 4F8, or 5L20 to neutralize or enhance
DENV1 (A), DENV2 (B), DENV3 (C), or DENV4 (D) is shown over a concentration range. Flow cytometric neutralization assays were performed with
U937-DC-SIGN cells. ADE assays were performed using U937 Fc receptor expressing cells. In the absence of antibody, the percentages of U937 cells infected in
the ADE assay with DENV1, DENV2, DENV3, or DENV4 were 0.06, 0.17, 0.31, and 1.31%, respectively.
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portion of E protein. All of the DIII antibodies were cross-reactive,
and only one (2J20) had neutralizing activity. Characterization of
the 26 fully cross-reactive anti-E protein MAbs showed that most,
but not all, were directed toward the DI/II region.
E protein specific human B cells specifying strongly neutraliz-
ing antibodies are rare. Of the 29 human anti-envelope antibodies
generated, only three (MAbs 5J7, 2J20, and 2D22) met our defini-
tion of moderate to strongly neutralizing (Neut50  1.0 g/ml):
two following primary infection and one following secondary in-
fection. Two of the three antibodies, MAbs 5J7 and 2J20, exhibited
cross-reactive binding to all four DENVs in an ELISA and yet
strongly neutralized virions of only one serotype. 2D22 was
DENV2 type-specific both for binding and neutralization. MAb
2J20 bound to DIII and 5J7 to DI/II of the E protein. 2D22 was
particularly interesting because it bound to the virus particle but
not to any of the recombinant protein constructs used in the pres-
ent study. There are several plausible explanations for these obser-
vations. The 2D22 epitope may be located in a region of E that is
not included in the recombinant constructs, given that the
membrane- proximal regions were removed in the design of these
constructs in order to make them soluble. In addition, the con-
formation of the epitope may be altered during preparation for
ELISA or Western blotting. Alternatively, the epitope recog-
nized by this very interesting human antibody might be very
complex, involving the interface of neighboring E proteins.
Indeed, human MAbs that only bind a West Nile virus E pro-
tein epitope that is preserved on the intact virion but not re-
combinant protein have recently been described (47). The
maximum percentage of virus neutralization for MAbs 5J7 and
2D22 differed greatly. The maximum percentage of neutraliza-
tion for MAb 5J7 was nearly 100%, whereas MAb 2D22 could
neutralize only about 60% at the highest concentration of an-
tibody tested. This finding not only suggests that the MAbs
recognize different epitopes but also probably means that they
use different mechanisms of neutralization.
ADE activity, not neutralization, was the dominant functional
activity noted for the E-protein specific antibodies in the present
study. All but two anti-E protein antibodies enhanced infection
of at least one serotype at the concentration tested (1 g/ml).
Strongly neutralizing serotype-specific MAb 2D22 and fully cross-
reactive weakly neutralizing MAb 3H4 were the only MAbs that
had no detectable ability to enhance DENV infection at this initial
concentration. Interestingly, further dilution of 2D22, well below
the concentration where enhancement occurred with all of the
other MAbs, demonstrated enhancement of infection (data not
shown). Maximum ADE activity (25-fold) was seen at a concen-
tration of 0.025 g/ml, compared to between 0.1 and 1.0 g/ml,
seen for other MAbs in our panel. Sixteen antibodies met our
definition for mediating strong (25-fold) enhancement of at
least one serotype, including the DIII-binding strongly neutraliz-
ing antibody 2J20. Taken together, these data show that the po-
tency of neutralization does not always inversely correlate with the
strength of enhancement, since strongly neutralizing antibodies
also were strongly enhancing at lower concentrations, whereas
MAb 3H4 that was weakly neutralizing did not display enhancing
activity. It is important to note that the human antibody response
to dengue infection seems to rarely include antibodies that are able
to separate neutralization from enhancement, as exemplified by
MAb 2D22. This MAb possesses potent serotype-specific neu-
tralization activity without the ability to enhance infection at
the typical concentration range seen with weakly neutralizing
cross-reactive MAbs. Understanding the specificity of these rare
but very important antibodies is critical for the rational design of
a dengue vaccine. Preliminary data suggest that this antibody rec-
ognizes the E protein but binds to a feature that is only present in
the E protein in intact virion particles and not in recombinant
soluble forms of E protein or recombinant domains of E.
Interpretation of E protein specific antibody cross-reactivity is
complex, since not only do field strains of DENV circulate with
serotypic differences, but also there are significant genotypic dif-
ferences within serotypes. Furthermore, some antibodies to flavi-
virus E proteins are known to cross-react with diverse flaviviruses
(42). Since our subjects acquired DENV infection in Asia and the
Americas, the responses theoretically could be affected by undocu-
mented exposure to Japanese encephalitis virus or yellow fever virus
or other flavivirus infection or vaccination. However, the subjects
studied here did have documented DENV infection histories, and the
majority of antibodies cross-react with all four DENV serotypes. An-
other caveat about these studies of cross-reactivity and ADE is that we
used an in vitro model of enhanced infection with U937 cells, a hu-
man leukemic monocyte lymphoma cell line. It could be of interest in
future studies to explore the effect of these antibodies in primary
human cells such as monocytes.
Nearly one-quarter, 8 of 37, of the human anti-DENV antibod-
ies identified here were prM protein specific. Compared to the
number of anti-E protein antibodies obtained after primary infec-
tion versus after secondary infection (i.e., 24 after primary infec-
tion and 5 after secondary infection), there appeared to be a
greater percentage of anti-prM protein MAbs generated from sub-
jects after secondary infection (17% anti-E, and 50% anti-prM).
This finding suggests that the human antibody response to prM
protein may be increased relative to the response to E protein
following a secondary infection. This observation has been sug-
gested previously by others using Western blotting methods and
dengue-immune sera (23). The most prominent characteristic
noted in the panel of human anti-prM MAbs here was the degree
of cross-reactivity. All eight MAbs were fully cross-reactive, bind-
ing all four dengue serotypes in ELISA at the lowest concentration
tested (1 ng/l) using whole virus as antigen. All but one prM
protein-specific MAb met our definition for strong (25-fold)
enhancement of infection. Further characterization of these eight
MAbs showed that all were directed toward the “pr” portion of the
prM protein, since they bound to the recombinant “pr” fragment
protein in ELISA. Interestingly, however, two anti-prM protein
MAbs met our definition for moderate to strongly neutralizing
activity (Neut50  1.0 g/ml): MAbs 2H12 and 2M2. These two
pr-specific MAbs demonstrated serotype-specific neutralizing ac-
tivity despite being fully cross-reactive. The physiologic signifi-
cance of potent neutralization of DENV by prM-specific antibod-
ies that should recognize only immature particles is uncertain but
bears further exploration.
In summary, the human B cell response encoding DENV-
specific antibodies is complex. Human antibody-mediated neu-
tralizing activity is directed to both structural proteins and diverse
epitopes in those proteins. Most of the E protein-specific antibod-
ies exhibit ADE activity, whereas only rare clones possess potent
neutralizing activity. The antibodies that do neutralize exhibit fea-
tures that suggest differing mechanisms of neutralization. Most
intriguingly, the most potent serotype specific neutralizing anti-
body identified recognizes an occult epitope that is present in virus
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particles but not represented in recombinant antigens. Discovery
of the structure and nature of the epitopes for this unique MAb
and similar antibodies in the future could point the way toward
better rational design of dengue vaccine antigens. Unexpectedly,
some prM-specific antibodies exhibited relatively potent neutral-
izing activity, which is of interest for future studies.
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